Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy
Key facts
- Who runs it
- Institut du Cancer de Montpellier - Val d'Aurelle
- Where
- France3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 29 people enrolled
- Started
- 15 Jul 2017
- Ended
- 23 Nov 2023
- Type of study
- Interventional
- Treatments tested
- Cisplatin injection
- radiotherapy
- Record updated
- 18 May 2025
- Why it stopped
- insufficient recruitment
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Age ≥ 18 years
- HPV-positive cervical cancer proven* by biopsy
- All FIGO stages cervical cancers which are the matter for radio-chemotherapy and exclusive brachytherapy indications
- ECOG performance status ≤2
- Ability to give informed consent
- Patients must be affiliated to a Social Security System
- Patient information and written informed consent form signed
Who cannot take part
- Known autoimmune disorder
- History of HIV and/ or hepatitis infection
- History of pelvic radiation or radio-chemotherapy
- Recurrent or metastatic cervical cancer
- History of other malignancy within the previous 5 years (except for appropriately treated melanoma skin carcinoma)
- Patients with psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
- Adenocarcinoma of cervix
- Contra-indication for cisplatin
- Patient pregnant and/or breastfeeding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Perspectives:
Read full original descriptionShow less
* To set-up another clinical trial with this specific phenotype as the main stratification factor. Therefore a more aggressive or a more specific systemic treatment (with or without an immunomodulator) could be proposed to those selected patients in the field of personalized medicine. * To evaluate the use of the smear as a surrogate non-invasive technique to biopsy for immunomonitoring. * To use the CTC/PD-L1 assay as a liquid biopsy in future clinical trials for stratification and monitoring of cancer patients undergoing immune checkpoint treatments. This specific subset of CTCs might represent metastatic cells with a high potential to escape T cell-mediated lysis and might therefore be the actual targets of immunotherapy.
The group in the trial
- CisplatinTreatment being tested
Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
Treatment: Cisplatin injection and radiotherapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy (IMMUVIX)
- Record updated
- 18 May 2025